- Research Article
- Published:
Silencing of the type 1 insulin-like growth factor receptor increases the sensitivity to apoptosis and inhibits invasion in human lung adenocarcinoma A549 cells
Cellular & Molecular Biology Letters volume 12, pages 556–572 (2007)
Abstract
The type 1 insulin-like growth factor receptor (IGF-1R), which is over-expressed or activated in many human cancers, including lung cancer, mediates cancer cell proliferation and metastasis. Several studies indicate that blocking IGF-1R expression can inhibit tumor cell proliferation and metastasis. In this study, inhibition of the endogenous IGF-1R by recombinant adenoviruses encoding short hairpin RNAs against IGF-1R was found to significantly suppress IGF-1R expression, arrest the cell cycle, enhance the apoptotic response, and inhibit proliferation, adhesion, invasion and migration in A549 cells. Moreover, silencing IGF-1R decreases the expression of invasive-related genes including matrix metalloproteinase-2 (MMP-2), MMP-9, and urokinase-plasminogen activator (u-PA), and the phosphorylation of Akt and ERK1/2. These results suggest that the silencing of IGF-1R has the potential to be an effective cancer gene therapy strategy for human lung cancer.
Abbreviations
- ECM:
-
extracellular matrix
- HRP:
-
horseradish peroxidise
- IGF-1R:
-
type 1 insulin-like growth factor receptor
- McAb:
-
monoclonal antibody
- MMP:
-
matrix metalloproteinase
- NSCLC:
-
non-small cell lung cancer
- PcAb:
-
polyclonal antibody
- shRNA:
-
short hairpin RNA
- u-PA:
-
urokinase-plasminogen activator
References
Mezzetti, M., Panigalli T., Giuliani, L., Raveglia, F., Giudice, F.L. and Meda, S. Personal experience in lung cancer sleeve lobectomy and sleeve pneumonectomy. Ann. Thorac. Surg. 73 (2002) 1736–1739.
Greenlee, R.T., Murray, T., Bolden, S. and Wingo, P. A. Cancer statistics, 2000: CA Cancer J. Clin. 50 (2000) 7–33.
Jiang, Y., Rom, W.N., Yie, T.A., Chi, C.X. and Tchou-Wong, K.M. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene 18 (1999) 6071–6077.
Min, Y., Adachi, Y., Yamamotom H., Ito, H., Itoh, F., Lee, C.T., Nadaf, S., Carbone, D.P. and Imai, K. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res. 64 (2003) 32–41.
Zhang, D., Bar-Eli, M., Meloche, S. and Brodt, P. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J. Biol. Chem. 279 (2004) 19683–19690.
LeRoith, D., Werner, H., Beitner-Johnson, D. and Roberts, C.T. Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 16 (1995) 143–163.
Nakanishi, Y., Mulshine, J.L., Kasprzyk, P.G., Natale, R.B., Maneckjee, R., Avis, I., Treston, A.M., Gazdar, A.F., Minna, J.D. and Cuttitta, F. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J. Clin. Invest. 82 (1988) 354–359.
Kaleko, M., Rutter, W.J. and Miller, A.D. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol. Cell. Biol. 10 (1990) 464–473.
Remacle-Bonnet, M.M., Garrouste, F.L., Heller, S., Andre, F., Marvaldi, J.L. and Pommier, G.J. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res. 60 (2000) 2007–2017.
Singh, P. Insulin-like growth factor system in growth, development and carcinogenesis. J. Clin. Lig. Assay 23 (2000) 214–232.
Scotlandi, K., Maini, C., Manara, M.C., Benini, S., Serra, M., Cerisano, V., Strammiello, R., Baldini, N., Lollini, P.L., Nanni, P., Nicoletti, G. and Picci, P. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing’s sarcoma cells. Cancer Gene Ther. 9 (2002) 296–307.
Turner, B.C., Haffty, B.G., Narayanan, L., Yuan, J., Havre, P.A., Gumbs, A.A., Kaplan, L., Burgaud, J.L., Carter, D., Baserga, R. and Glazer, P.M. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 57 (1997) 3079–3083.
Wu, Y., Tewari, M., Cui, S. and Rubin, R. Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death. J. Cell Physiol. 168 (1996) 499–509.
Grimberg, A. and Cohen, P. Growth hormone and prostate cancer: guilty by association? J. Endocrinol. Invest. 22 (1999) 64–73.
Ma, J., Pollak, M., Giovannucci, E., Chan, J.M., Tao, Y., Hennekens, C. and Stampfer, M.J. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm. IGF Res. 10 (2000) S28–29.
Yu, H., Spitz, M.R., Mistry, J., Gu, J., Hong, W.K. and Wu, X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl. Cancer Inst. 91 (1999) 151–1516.
Maile, L.A., Imai, Y., Clarke, J.B. and Clemmons, D.R. Insulin-like growth factor I increases alpha Vbeta 3 affinity by increasing the amount of integrin-associated protein that is associated with non-raft domains of the cellular membrane. J. Biol. Chem. 277 (2002) 1800–1805.
Playford, M.P., Bicknell, D., Bodmer, W.F. and Macaulay, V.M. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc. Natl. Acad. Sci. USA. 97 (2000) 12103–12108.
Sachdev, D., Hartell, J.S., Lee, A.V., Zhang, X. and Yee, D. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J. Biol. Chem. 279 (2004) 5017–5024.
Cockett, M.I., Murphy, G., Birch, M.L., O’Connell, J.P., Crabbe, T., Millican, A.T., Hart, I.R. and Docherty, A.J. Matrix metalloproteinases and metastatic cancer. Biochem. Soc. Symp. 63 (1998) 295–313.
Kleiner, D.E. and Stetler-Stevenson, W.G. Matrix metalloproteinases and metastasis. Cancer Chemother. Pharmacol. 43 (1999) S42–51.
Ohbayashi, H. Matrix metalloproteinases in lung diseases. Curr. Protein Pept. Sci. 3 (2002) 409–421.
Maloney, E.K., McLaughlin, J.L., Dagdigian, N.E., Garrett, L.M., Connors, K.M., Zhou, X.M., Blattler, W.A., Chittenden, T. and Singh, R. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 63 (2003) 5073–5083.
Chernicky, C.L., Yi, L., Tan, H., Gan, S.U. and Ilan, J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther. 7 (2000) 384–395.
Dykxhoorn, D.M., Novina, C.D. and Sharp, P.A. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 4 (2003) 457–467.
Bohula, E.A., Salisbury, A.J., Sohail, M., Playford, M.P., Riedemann, J., Southern, E.M. and Macaulay, V.M. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J. Biol. Chem. 278 (2003) 15991–15997.
Lee, C.T., Park, K.H., Adachi, Y., Seol, J.Y., Yoo, C.G., Kim, Y.W., Han, S.K., Shim, Y.S., Coffee, K., Dikov, M.M. and Carbone, D.P. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate anti-tumor effects on lung cancer. Cancer Gene Ther. 10 (2003) 57–63.
Zhang, H., Ma, G., Dong, M., Zhao, M., Shen, X., Ma, Z. and Guo, K. Epidermal growth factor promotes invasiveness of pancreatic cancer cells through NF-kappaB-mediated proteinase productions. Pancreas 32 (2006) 101–109.
Scotlandi, K., Benini, S., Nanni, P., Lollini, P.L., Nicoletti, G., Landuzzi, L., Serra, M., Manara, M.C., Picci, P. and Baldini, N. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing’s sarcoma in athymic mice. Cancer Res. 58 (1998) 4127–4131.
Lee, C.T., Wu, S., Gabrilovich, D., Chen, H., Nadaf-Rahrov, S., Ciernik, I.F. and Carbone, D.P. Anti-tumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res. 56 (1996) 3038–3041.
Dunn, S.E., Ehrlich, M., Sharp, N.J., Reiss, K., Solomon, G., Hawkins, R., Baserga, R. and Barrett, J.C. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 58 (1998) 3353–3361.
Zamore, P.D. RNA interference: listening to the sound of silence. Nature Structural Biology. 8 (2001) 746–750.
Miyagishi, M. and Taira, K. U6 promoter-driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nature Biotechnology 20 (2002) 497–500.
Dong, A.Q., Kong, M.J., Ma, Z.Y., Qian, J.F. and Xu, X.H. Down-regulation of IGF-IR using small, interfering, hairpin RNA (siRNA) inhibits growth of human lung cancer cell line A549 in vitro and in nude mice. Cell Biol. Int. 31 (2007) 500–507.
Dunn, S.E., Torres, J.V., Oh, J.S., Cykert, D.M. and Barrett, J.C. Upregulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res. 61 (2001) 1367–1374.
Salatino, M., Schillaci, R., Proietti, C.J., Carnevale, R., Frahm, I., Molinolo, A.A., Iribarren, A., Charreau, E.H. and Elizalde, P.V. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulinlike growth factor receptor mRNA involves inactivation of ErbBs, PI 3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene. 23 (2004) 5161–5174.
Tai, Y.T., Podar, K., Catley, L., Tseng, Y.H., Akiyama, M., Shringarpure, R., Burger, R., Hideshima, T., Chauhan, D., Mitsiades, N., Richardson, P., Munshi, N.C., Kahn, C.R., Mitsiades, C. and Anderson, K.C. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3′-kinase/AKT signaling. Cancer Res. 63 (2003) 5850–5858.
Muller, D., Breathnach, R., Engelmann, A., Millon, R., Bronner, G., Flesch, H., Dumont, P., Eber, M. and Abecassis, J. Expression of collagenaserelated metalloproteinase genes in human lung or head and neck tumours. Int. J. Cancer. 48 (1991) 550–556.
Kanayama, H., Yokota, K., Kurokawa, Y., Murakami, Y., Nishitani, M. and Kagawa, S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 82 (1998) 1359–1366.
Schmitt, M., Harbeck, N., Thomssen, C., Wilhelm, O., Magdolen, V., Reuning, U., Ulm, K., Hofler, H., Janicke, F. and Graeff, H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 78 (1997) 285–296.
Pulukuri, S.M., Gondi, C.S., Lakka, S.S., Jutla, A., Estes, N., Gujrati, M. and Rao, J.S. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J. Biol. Chem. 280 (2005) 36529–36540.
Kondraganti, S., Mohanam, S., Chintala, S.K., Kin, Y., Jasti, S.L., Nirmala, C., Lakka, S.S., Adachi, Y., Kyritsis, A.P., Ali-Osman, F., Sawaya, R., Fuller, G.N. and Rao, J.S. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res. 60 (2000) 6851–6855.
Grzmil, M., Hemmerlein, B., Thelen, P., Schweyer, S. and Burfeind, P. Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression. J. Pathol. 202 (2004) 50–59.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ma, Z., Dong, A., Kong, M. et al. Silencing of the type 1 insulin-like growth factor receptor increases the sensitivity to apoptosis and inhibits invasion in human lung adenocarcinoma A549 cells. Cell Mol Biol Lett 12, 556–572 (2007). https://doi.org/10.2478/s11658-007-0022-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2478/s11658-007-0022-1